Merck Can Block Teva on Generic Temodar as Court Rejects Appeal
This article is for subscribers only.
The U.S. Supreme Court left intact a ruling that lets Merck & Co. block Teva Pharmaceutical Industries Ltd. from selling a generic form of the brain-cancer drug Temodar until 2013.
The justices today turned away an appeal by Teva’s Barr Laboratories and Barr Pharmaceuticals units, which contended that a Merck patent protecting the drug was unenforceable. A U.S. appeals court had rejected that argument.